Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL).

Trial Profile

Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database.
    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top